Your browser doesn't support javascript.
loading
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
Plotkin, Scott R; Messiaen, Ludwine; Legius, Eric; Pancza, Patrice; Avery, Robert A; Blakeley, Jaishri O; Babovic-Vuksanovic, Dusica; Ferner, Rosalie; Fisher, Michael J; Friedman, Jan M; Giovannini, Marco; Gutmann, David H; Hanemann, Clemens Oliver; Kalamarides, Michel; Kehrer-Sawatzki, Hildegard; Korf, Bruce R; Mautner, Victor-Felix; MacCollin, Mia; Papi, Laura; Rauen, Katherine A; Riccardi, Vincent; Schorry, Elizabeth; Smith, Miriam J; Stemmer-Rachamimov, Anat; Stevenson, David A; Ullrich, Nicole J; Viskochil, David; Wimmer, Katharina; Yohay, Kaleb; Huson, Susan M; Wolkenstein, Pierre; Evans, D Gareth.
Afiliación
  • Plotkin SR; Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA. Electronic address: splotkin@mgh.harvard.edu.
  • Messiaen L; Department of Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL.
  • Legius E; Department of Human Genetics, Member of ERN GENTURIS, KU Leuven and University Hospital, Leuven, Belgium.
  • Pancza P; Children's Tumor Foundation, New York, NY.
  • Avery RA; Division of Ophthalmology, The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Blakeley JO; Comprehensive Neurofibromatosis Center, Johns Hopkins Medicine, The Johns Hopkins Hospital, Baltimore, MD.
  • Babovic-Vuksanovic D; Department of Clinical Genomics, Mayo Clinic College of Medicine and Science, Rochester, MN.
  • Ferner R; Neurology, Guy's and St. Thomas' Hospital and NHS Trust, London, United Kingdom.
  • Fisher MJ; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Friedman JM; Department of Medical Genetics, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Giovannini M; Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA and Jonsson Comprehensive Cancer Center (JCCC), University of California, Los Angeles, CA.
  • Gutmann DH; Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, MO.
  • Hanemann CO; Institute of Translational and Stratified Medicine, Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom.
  • Kalamarides M; Department of Neurosurgery, Hospital Pitie-Salpetriere, Sorbonne Université, Paris, France.
  • Kehrer-Sawatzki H; Institute of Human Genetics, University of Ulm, Ulm, Germany.
  • Korf BR; Department of Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL.
  • Mautner VF; Department of Neurology, University Hospital of Hamburg-Eppendorf, Hamburg, Germany.
  • MacCollin M; Pediatric Neurology, Bend, OR.
  • Papi L; The Department of Experimental and Clinical, Medical Genetics Unit, Biomedical Sciences "Mario Serio," University of Florence, Florence, Italy.
  • Rauen KA; Department of Pediatrics, University of California Davis, Sacramento, CA.
  • Riccardi V; The Neurofibromatosis Institute, La Crescenta, CA.
  • Schorry E; Medical Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Smith MJ; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Member of ERN GENTURIS, Division of Evolution, Infection and Genomics, University of Manchester, Manchester, UK.
  • Stemmer-Rachamimov A; Department of Pathology, Massachusetts General Hospital, Boston, MA.
  • Stevenson DA; Division of Medical Genetics, Department of Pediatrics, Stanford University, Stanford, CA.
  • Ullrich NJ; Department of Neurology, Boston Children's Hospital, Boston, MA.
  • Viskochil D; Medical Genetics, University of Utah, Salt Lake City, UT.
  • Wimmer K; Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
  • Yohay K; Departments of Neurology and Pediatrics, NYU Langone Health, New York, NY.
  • Huson SM; Clinical Genetics, (Formerly) Manchester Center for Genomic Medicine, Manchester University Hospitals, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
  • Wolkenstein P; Service de Dermatologie, Assistance Publique-Hôpital Paris (AP-HP), Hôpital Henri-Mondor, UPEC, Créteil, France.
  • Evans DG; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Member of ERN GENTURIS, Division of Evolution, Infection and Genomics, University of Manchester, Manchester, UK.
Genet Med ; 24(9): 1967-1977, 2022 09.
Article en En | MEDLINE | ID: mdl-35674741
ABSTRACT

PURPOSE:

Neurofibromatosis type 2 (NF2) and schwannomatosis (SWN) are genetically distinct tumor predisposition syndromes with overlapping phenotypes. We sought to update the diagnostic criteria for NF2 and SWN by incorporating recent advances in genetics, ophthalmology, neuropathology, and neuroimaging.

METHODS:

We used a multistep process, beginning with a Delphi method involving global disease experts and subsequently involving non-neurofibromatosis clinical experts, patients, and foundations/patient advocacy groups.

RESULTS:

We reached consensus on the minimal clinical and genetic criteria for diagnosing NF2 and SWN. These criteria incorporate mosaic forms of these conditions. In addition, we recommend updated nomenclature for these disorders to emphasize their phenotypic overlap and to minimize misdiagnosis with neurofibromatosis type 1.

CONCLUSION:

The updated criteria for NF2 and SWN incorporate clinical features and genetic testing, with a focus on using molecular data to differentiate the 2 conditions. It is likely that continued refinement of these new criteria will be necessary as investigators study the diagnostic properties of the revised criteria and identify new genes associated with SWN. In the revised nomenclature, the term "neurofibromatosis 2" has been retired to improve diagnostic specificity.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Neurofibromatosis 2 / Neurofibromatosis 1 / Neurofibromatosis / Neurilemoma Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Neurofibromatosis 2 / Neurofibromatosis 1 / Neurofibromatosis / Neurilemoma Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2022 Tipo del documento: Article